Carisma Therapeutics, Inc. (NASDAQ: CARM) had its "neutral" rating re-affirmed by analysts at HC Wainwright.
Carisma Therapeutics, Inc. (NASDAQ: CARM) was downgraded by analysts at Baird R W from a "strong-buy" rating to a "hold" rating.
Carisma Therapeutics, Inc. (NASDAQ: CARM) was downgraded by analysts at Robert W. Baird from an "outperform" rating to a "neutral" rating. They now have a $1.00 price target on the stock, down previously from $10.00.
Carisma Therapeutics, Inc. (NASDAQ: CARM) had its "in-line" rating re-affirmed by analysts at Evercore ISI. They now have a $0.70 price target on the stock, down previously from $4.00.
Carisma Therapeutics, Inc. (NASDAQ: CARM) was downgraded by analysts at BTIG Research from a "buy" rating to a "neutral" rating.